Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.39 |
| ▸ | MAPT | P10636 | 3/20 | 0.39 |
| ▸ | GAA | P10253 | 2/20 | 0.39 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.38 |
| ▸ | PKM | P14618 | 2/20 | 0.38 |
| ▸ | MEN1 | O00255 | 1/20 | 0.37 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.37 |
| ▸ | NSD2 | O96028 | 1/20 | 0.37 |
| ▸ | PRMT5 | O14744 | 1/20 | 0.36 |
| ▸ | WDR77 | Q9BQA1 | 1/20 | 0.36 |
| ▸ | LMNA | P02545 | 1/20 | 0.36 |
| ▸ | DRD2 | P14416 | 1/20 | 0.35 |
| ▸ | DRD4 | P21917 | 1/20 | 0.35 |
| ▸ | DRD3 | P35462 | 1/20 | 0.35 |
| ▸ | SMYD3 | Q9H7B4 | 2/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6301580 | 0.91 | MAPT (0.39) | ALDH1A1MAPTGAARXFP1PKM | |
| SCHEMBL6295486 | 0.89 | MAPT (0.38) | ALDH1A1MAPTGAARXFP1PKM | |
| SCHEMBL6301733 | 0.75 | DRD2 (0.49) | ALDH1A1MAPTGAARXFP1KMT2A | |
| SCHEMBL6297460 | 0.74 | CYP11B1 (0.44) | ALDH1A1MAPTKMT2ANSD2DRD2 | |
| SCHEMBL6296965 | 0.74 | CYP11B1 (0.44) | ALDH1A1MAPTGAAPKMKMT2A | |
| SCHEMBL6295473 | 0.71 | CYP11B1 (0.43) | ALDH1A1MAPTGAAPKMKMT2A | |
| SCHEMBL6295828 | 0.69 | CYP11B1 (0.44) | ALDH1A1MAPTPKMKMT2ANSD2 | |
| SCHEMBL14572100 | 0.69 | LTA4H (0.43) | SMYD3 | |
| SCHEMBL941445 | 0.69 | GAA (0.56) | ALDH1A1MAPTGAAPKMKMT2A | |
| SCHEMBL7343583 | 0.69 | ALDH1A1 (0.46) | ALDH1A1MAPTGAARXFP1PKM |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6951855-B2 | Benzoxazinone derivatives for use in the treatment of angiogenesis | ASTRAZENECA AB (SE) | 2005-10-04 | — | — | US | disclosed |
| US-20040122006-A1 | Benzoxazinone derivatives for use in the treatment of angiogenesis | ASTRAZENECA AB (SE) | 2004-06-24 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040122006-A1 | Benzoxazinone derivatives for use in the treatment of angiogenesis | HAX1, VEGFA, HYOU1 | ALDH1A1 595/4885MAPT 4831/4885GAA 4218/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.